The Clinical Relevance of p16 and p53 Status in Patients with Squamous Cell Carcinoma of the Vulva

Table 2

Univariate outcome analysis by Cox regression for disease-free survival and disease-specific survival.

Variable	Disease-free survival			Disease-specific survival
	HR	95% CI	value	HR	95% CI	value
Age >65 years (ref—age ≤65 yrs)	1.62	(0.84–3.10)	0.15	2.32	(0.90–6.05)	0.09
Lesion size >4 cms (ref—≤4 cm)	2.05	(1.07–3.92)	0.03	8.05	(3.10–21.05)	<0.001
Depth of invasion >5 mm (ref—≤5 mm)	1.16	(0.62–2.20)	0.64	3.65	(1.40–9.51)	0.008
Lymph node metastases	3.30	(1.73–6.22)	<0.001	23.34	(5.40–101.12)	<0.001
Perineural invasion	2.23	(1.02–5.00)	0.05	3.20	(1.21–8.26)	0.02
LVSI	1.43	(0.70–3.02)	0.35	1.54	(0.56–4.23)	0.41
Differentiation—mod/poor (ref—well-differentiated)	1.20	(0.61–2.31)	0.62	2.62	(0.90–7.85)	0.09
Adjuvant radiotherapy	2.00	(0.92–3.91)	0.08	3.60	(1.45–8.73)	0.005
P16 positive (ref—p53 positive)	0.50	(0.30–0.95)	0.03	0.51	(0.21–1.24)	0.14

HR: hazard ratio; CI: confidence interval; ref: reference group; LVSI: lymphovascular space invasion.